Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrilumab in Moderate to Severe Crohn's Disease
NCT01696396Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2012
- Primary completion
- Dec 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of abrilumab in Crohn's disease, sponsored by Amgen. Started Dec 2012; status: completed.
02
Drugs
abrilumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01696396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01696396.